RhumbLine Advisers
VYNE icon

RhumbLine Advisers’s VYNE Therapeutics VYNE Stock Holding History

RhumbLine Advisers’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,696
Closed -$332K – 3111
2021
Q1 		$332K Buy
2,696
+181
+7% +$26.2K ﹤0.01% 2668
2020
Q4 		$286K Buy
2,515
+483
+24% +$60.7K ﹤0.01% 2689
2020
Q3 		$243K Buy
2,032
+38
+2% +$4.43K ﹤0.01% 2611
2020
Q2 		$248K Buy
1,994
+1,329
+200% +$180K ﹤0.01% 2668
2020
Q1 		$128K Buy
665
+380
+133% +$119K ﹤0.01% 2722
2019
Q4 		$95K Buy
285
+4
+1% +$1.33K ﹤0.01% 2876
2019
Q3 		$91K Buy
281
+27
+11% +$8.72K ﹤0.01% 2901
2019
Q2 		$109K Buy
254
+84
+49% +$41.6K ﹤0.01% 2917
2019
Q1 		$96K Buy
170
+9
+6% +$4.32K ﹤0.01% 2864
2018
Q4 		$48K Buy
+161
New +$72.1K ﹤0.01% 2946

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

RhumbLine Advisers's VYNE Position: Q2 2021 in Review

RhumbLine Advisers sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 2,696 shares — an estimated $332K sold.

RhumbLine Advisers first reported a position in VYNE in Q4 2018 and held it in 10 quarters. The position peaked at $332K in Q1 2021. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

  • RhumbLine Advisers reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 2,696 VYNE Therapeutics shares in Q2 2021, an estimated $332K.
  • RhumbLine Advisers first reported a position in VYNE Therapeutics in Q4 2018 and held it in 10 quarters.
  • RhumbLine Advisers's VYNE Therapeutics position peaked at $332K in Q1 2021.
  • 72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.